Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism.

Patel, Shivani; Chin, Venessa; Greenfield, Jerry R

Patel, Shivani; Chin, Venessa; Greenfield, Jerry R.

Afiliação

Patel S; Department of Diabetes and Endocrinology, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia.
Chin V; Diabetes and Metabolism, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
Greenfield JR; The Kinghorn Cancer Centre, Sydney, New South Wales, Australia.

Endocrinol Diabetes Metab Case Rep ; 20192019 Dec 12.

Article em En | MEDLINE | ID: mdl-31829972

Palavras-chave

2019; Adult; Australia; Autoimmune disorders; Beta-hydroxybutyrate; Bicarbonate; C-peptide (blood); Cortisol; Cortisol (9am); December; Diabetes mellitus type 1; Diabetic ketoacidosis; Durvalumab*; FT4; Fatigue; Female; GADA; Glucose (blood); Haemoglobin A1c; Hyperglycaemia; Hypothyroidism; Insulin; Insulin Aspart; Insulin glargine; Levothyroxine; Oncology; Pancreas; Polydipsia; Polyuria; TSH; Thyroid; Thyroid function; Thyroxine (T4); Unusual effects of medical treatment; Vision - blurred; Weight loss; White; pH (blood)

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Idioma: En Revista: Endocrinol Diabetes Metab Case Rep Ano de publicação: 2019 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google